Introduction
Acute myeloid leukemia (AML) is the most frequent leukemia in adults with improving but still limited treatment possibilities, notably in elderly patients 1, 2 . It arises by malignant transformation of myeloid progenitor cells. Among the contributing genetic lesions, mutations in the class III receptor tyrosine kinase (RTK) FMS-like tyrosine kinase 3 (FLT3) occur in about 30% of patients 3 . The prevalent type of FLT3 mutations are internal tandem duplications (ITD) of amino acid stretches in the juxtamembrane domain or in the tyrosine kinase domain 4, 5 , which confer cytokine-independent proliferation and resistance to apoptosis, and causally contribute to AML in combination with additional genetic lesions 1 . As compared with the ligand-activated wildtype FLT3, FLT3 ITD mutants exhibit not only elevated but also altered signaling quality, with very pronounced activation of STAT5 as one characteristic feature 6, 7 . FLT3 ITD causes also the production of high levels of reactive oxygen species (ROS) 8, 9 .
Signal transduction of RTKs is regulated by protein-tyrosine phosphatases (PTPs). PTPs prevent ligand-independent RTK activation, and contribute to modulation and termination of ligand-induced signaling 10 . The activity of PTPs is regulated at several different levels 11 . One regulatory principle is the reversible oxidation of the PTP active-site cysteine, leading to reversible inactivation 12, 13 . Temporary inactivation of negatively regulating PTPs by this mechanism is believed to be important for efficient RTK signal propagation in the cell 14 . A major ROS species causing cellular PTP oxidation is hydrogen peroxide (H 2 O 2 ), which can be generated by a dismutase reaction from superoxide anions, the reaction products of NADPHoxidases. Activation of the NADPH oxidase isoform 1 (NOX1) occurs downstream of RTK activation, and involves activation and membrane translocation of the small GTPase Rac1 15 .
ROS generation in the cell is counteracted by efficient ROS decomposing systems 16 . These include peroxiredoxins (Prx), which have a very low K m for H 2 O 2 and can eliminate it even at low concentrations 17 .
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Relatively little is known about PTPs regulating FLT3 signal transduction. We have previously shown that the non-transmembrane PTPs PTP1B and SHP-1 can potently dephosphorylate FLT3 upon overexpression. Further, PTP1B appears important for suppressing signaling of newly synthesized FLT3 7, 18 . SHP-2 acts as a positive regulator, since it is important for Erk activation and proliferation induced by ligand-activated wildtype FLT3.
It is, however, dispensable for FLT3 ITD-mediated transformation 19 . We previously performed a shRNA-based screen to identify PTPs regulating wildtype FLT3. The initial screen assessed the effects of shRNAs for 20 PTPs on FL-induced Erk1/2 activation in wildtype FLT3-expressing 32D cells. Among several potentially relevant PTPs, we validated and characterized density-enhanced phosphatase-1 (DEP-1, systematic name PTPRJ, also CD148) as a negative regulator of wildtype FLT3 autophosphorylation and signaling 20 .
In the present study the role of DEP-1 for regulation of FLT3 ITD, the AML-related mutant 
Materials and Methods

Cell lines
HEK293, HEK293T cells, and the human AML cell lines, EOL-1, THP-1, RS4-11, MOLM-13 and MV4-11 were purchased from German Collection of Microorganisms and Cell
Cultures (DSMZ, Braunschweig, Germany Duyster (Technical University of Munich, Munich, Germany) and were maintained in HEPES-buffered RPMI-1640 (Biochrom, Berlin, Germany) with 10% heat-inactivated FBS, 1 mM sodium pyruvate and 2.5 ng/ml murine recombinant IL3 (Peprotech, London UK). 32D cells expressing human wildtype FLT3 or FLT3 ITD were described previously 20 and were employed for FLT3 autophosphorylation experiments.
AML patient samples
Leukemic cells from AML patient blood were isolated by Ficoll (Biochrom, Berlin, Germany) density gradient separation by standard procedures and processed for the experiments within 2-3 hours after taking. The patient study was approved by the local ethics committee and each patient gave written informed consent. The characteristics of AML patients included in this study are summarized in . ShRNA constructs for knockdown of endogenous DEP-1 in 32D cells were reported previously 20 .
Antibodies and Reagents
These are described in the Supplemetary Methods (Supplementary Information).
Transient transfections and generation of cell lines with altered gene expression
Transient transfections were carried out using branched polyethylenimine (PEI; SigmaAldrich, Deisenhofen, Germany; 40872-7) as described previously 21 . Further details are described in the Supplemetary Methods (Supplementary Information). 
ROS measurements
Measurements in HEK293 cells
PTP activity measurements
All the PTP activity-related work was carried out in an anaerobic chamber, Glovebox P10 R215T2s (TGS Glovebox Systemtechnik GmbH, Malsch, Germany). Cells were lysed using deoxygenated lysis buffer in the anaerobic chamber. The lysates were then subjected to immunoprecipitation of different PTP's. The immunoprecipitates were washed and then used for PTP activity assay using the Tyrosine Phosphatase assay system (Promega Corporation, Madison, USA). Control precipitations with non-specific IgG were carried out and assayed in parallel, and the activity values were subtracted from those for specific immunoprecipitates.
Alternatively, PTP activity was assayed with a 32 P-labeled peptide substrate as previously described 22 . General PTP oxidation was assessed using the "modified PTP in-gel assay" 13 , and PTEN oxidation was measured based on mobility alteration and with an alkylation method. A detailed description of these methods is provided in the Supplementary Information.
Biotin labeling of the DEP-1 catalytic cysteine DEP-1 was labeled with biotin using a previously described method 23 with several modifications. In brief, cells were lysed using deoxygenated lysis buffer at pH 5. 
Animal experiments
Animal experiments were carried out as described 7 
Results
Dysfunction of DEP-1 in FLT3 ITD-expressing cells
We have recently identified DEP-1 as a negative regulator of FLT3 phosphorylation, and Taken together, the described findings supported the notion that FLT3 ITD causes reduced DEP-1 activity compared with cells expressing wildtype FLT3 rather than alterations in mRNA or protein levels.
FLT3 ITD induces high levels of ROS
Given the high sensitivity of PTPs to oxidative inactivation 14 , and recently reported elevated ROS levels in FLT3 ITD-expressing cells 8, 9 , it appeared possible that DEP-1 inactivation in FLT3 ITD cells was caused by elevated ROS levels. To investigate this possibility, we first characterized the effects of FLT3 ITD on ROS production in different cell models.
High levels of ROS production were detectable with the fluorescent dye 5-(and-6)-carboxy- Figure S3A ).
Importantly, the human AML cell lines MV4-11 and MOLM13 harboring FLT3 ITD also produced high levels of ROS, whereas the AML lines THP-1, RS4-11, and EOL-1, which express wildtype FLT3, exhibited lower ROS levels ( Figure 2B ). Finally, primary blasts from AML patients expressing FLT3 ITD had a clear trend to higher ROS-levels than blasts from patients with wildtype FLT3 ( Figure 2C ). Comparison with FLT3 ITD allele-load revealed some positive correlation in that the four patients with highest allele loads also showed highest ROS levels (Supplementary Figure S4A , black bars). It should be noted that these measurements were no side-by-side comparisons, which may have obscured larger differences, as they were observed in a previous study 8 .
To identify possibilities of interference with FLT3 ITD-induced ROS production, we tested inhibition of several components of FLT3 ITD-dependent signaling. We also tested if activation of wildtype FLT3 would cause ROS production and had any effect on DEP-1 activity. Stimulation of wildtype FLT3-expressing 32D cells with FL indeed led to a small, but significant increase in detectable ROS, but this was not accompanied by an alteration in DEP-1 activity (suppelementary Figure S3D ).
FLT3 ITD-induced ROS is required for DEP-1 inactivation
The findings described above suggested that FLT3 ITD-induced ROS was involved in the To directly explore the effect of FLT3 ITD-mediated ROS production on the oxidation state of the DEP-1 catalytic cysteine, we employed a previously reported alkylation approach 23 . In this assay increased PTP oxidation is detected as a reduced signal from the alkylating agent, which is only reacting with the reduced form of PTPs. As shown in Figure 3C , It is likely that further PTPs contribute to regulation of FLT3 signaling activity. We therefore explored the effects of FLT3 ITD on activity of additional PTPs. We first tested PTP oxidation in 32D cells using a generic test, the "modified in-gel PTP assay" 13 . In this assay, reversibly oxidized PTPs can be detected based on their activity in SDS-PAGE gels containing a [ 32 P]labeled substrate. While cell treatment with H 2 O 2 as a positive control caused abundant PTP oxidation, the presence of FLT3 ITD did not lead to any pronounced PTP oxidation detectable in this assay ( Figure 4A ). It should be noted that this assay is not
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suitable to detect activity of transmembrane PTPs such as DEP-1. We also used immunoprecipitation-based assays to assess the activity of PTP1B, a ubiquitously expressed non-transmembrane PTP, and of CD45, an abundant hematopoietic transmembrane PTP.
While the former was not affected in activity by coexpression of FLT3 ITD (Figure 4B ), the latter showed only a trend of weakly reduced activity ( Figure 4C ). We also assessed another member of the PTP family, the lipid phosphatase Phosphatase and Tensin homolog (PTEN).
It negatively controls the PI3-kinase/AKT pathway, which is important for FLT3 ITD- For As shown in Figure 5A , treatment of the FLT3 ITD-harboring cell line MOLM-13 with AG1295 both led to reduction of ROS production, and to an elevation of DEP-1 activity. In contrast, AG1295-treatment of EOL-1 cells harboring wildtype FLT3 did not significantly change ROS production and DEP-1 activity was only weakly increased ( Figure 5B ). These data are consistent with the findings reported above, indicating that DEP-1 activity is inhibited by FLT3 ITD-driven ROS production.
The same assay was subsequently used on AML patient blasts. Interestingly, AG1295 caused reduced ROS levels and increased DEP-1 activity in FLT3 ITD-bearing blasts whereas no significant changes of this type were seen in patients with wildtype FLT3 ( Figure 5C , see supplementary Figure S4 for individual patient data).
Taken together, these findings indicated that DEP-1 activity is indeed compromised by FLT3
ITD-driven ROS production in vitro and in vivo.
For
ROS-mediated DEP-1 inactivation contributes to transformation of 32D cells by FLT3
ITD
If the described DEP-1 inactivation were important for FLT3 ITD-driven transformation, interfering with ROS generation should inhibit transformation in the presence of DEP-1. This was tested employing 32D cells stably expressing FLT3 ITD.
According to our preceding analysis, the NOX inhibitor DPI appeared to be a suitable agent since it effectively inhibited ROS production and restored DEP-1 activity. Since DPI also inhibits other flavoproteins and is toxic at high concentrations, we first carried out a titration experiment to estimate the minimal dose which would inhibit ROS substantially in these cells without severely impairing viability ( Supplementary Information, Figure S5A ). One µM DPI inhibited ROS production by about 50% but attenuated the growth of FLT3 ITD-expressing cells only partially as revealed by proliferation assays (Supplementary Information, Figure   S5B ). The effect of this non-toxic dose of DPI was then assayed in colony formation assays. DPI strongly impaired colony formation under these conditions ( Figure 6A ). We finally attempted to stably interfere with ROS production, in order to assess effects on transformation in vivo. Stable overexpression was achieved for Prx-1, a potent H 2 O 2 -scavenging enzyme ( Supplementary Information, Figure S5C ). Prx-1-overexpressing 32D cells formed lesser colonies in presence of endogenous DEP-1, and this effect was partly abrogated in DEP-1-depleted cells ( Figure 7A ). We further confirmed that Prx-1 overexpression reduced ROS production in the stable cell pools, and caused elevation of DEP-1 activity ( Figure 7B ). When injected into syngeneic mice, the FLT3 ITD-expressing 32D cells caused rapid MPD, regardless of the depletion of DEP-1 ( Figure 7C ). Upon Prx-1 overexpression, however, the development of MPD was significantly delayed for cells expressing DEP-1, whereas DEP-1 depleted cells were unaffected in their capacity to cause MPD ( Figure 7C ).
These data show that interference with the ROS production can attenuate transformation of 32D cells by FLT3 ITD in a DEP-1-dependent manner.
Discussion
Elimination of tumor suppressors by different molecular mechanisms, such as gene deletion, inactivating mutation, or silencing of transcription is a common phenomenon in oncogenesis. PTP oxidation as a regulatory feed-forward mechanism to enable and enhance growth factor signaling has been described earlier 17 
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It has been suggested by Sallmyr et al. 8 Figure S4 . 
